Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $26.34 USD
Change Today -0.12 / -0.45%
Volume 881.6K
DYAX On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 05/29/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Henry E. Blair

Co-Founder, Chairman of The Board and Member of Strategy & Science Committee, Dyax Corp.
AgeTotal Calculated CompensationThis person is connected to 14 board members in 3 different organizations across 7 different industries.

See Board Relationships
70$98,500

Background*

Mr. Henry E. Blair Co-founded Genzyme Corporation. Mr. Blair is a Co-Founder of Dyax Corporation and served as its Chief Executive Officer from 1997 to January 01, 2009 and the President from August 1995 to January 01, 2009. He co-founded Biocode, Inc., and GelTex Pharmaceuticals, Inc. Mr. Blair has been the Chairman of Dyax Corporation since August 1995 and as its Director since 1989. Mr. Blair served as a Director at Esperion Therapeutics, Inc.

Corporate Headquarters*

55 Network Drive
Burlington, Massachusetts 01803

United States

Phone: 617-225-2500
Fax: 617-225-2501

Board Members Memberships*

Former Director
Director
1981-N/A
Former Director
1981-2007
Co- Founder
1981-N/A
Former Director
1981-N/A
Co-Founder
1989-Present
Co-Founder, Chairman of The Board and Member of Strategy & Science Committee
1995-N/A
Former Director
2001-N/A
Former Director

Education*

There is no Education data available.

Other Affiliations*

Annual Compensation*

There is no Annual Compensation data available.

Stock Options*

There is no Stock Options data available.

Total Compensation*

Total Annual Cash Compensation$98,500
Total Calculated Compensation$98,500
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DYAX:US $26.34 USD -0.12

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Jon P. Stonehouse Chief Executive Officer, President and Executive Director
BioCryst Pharmaceuticals, Inc.
$633.7K
Leonard S. Schleifer M.D., Ph.D.Co-Founder, Chief Executive Officer, President, Executive Director and Ex-Officio Member of Technology Committee
Regeneron Pharmaceuticals, Inc.
$3.2M
Flemming Ornskov M.D., MBA, MPHChief Executive Officer, Managing Director and Director
Shire plc
$3.6M
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DYAX CORP, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.